Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504301![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 230 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504311![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 700 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504300![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 680 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504303![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 264 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 15 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504305![]() (US11034717, Compound A) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 200 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504306![]() (US11034717, Compound B) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 30 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504307![]() (US11034717, Compound C) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 1.75E+5 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504309![]() (US11034717, Compound L1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 150 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 7.5 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 15 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 42 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504311![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 29 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504309![]() (US11034717, Compound L1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 150 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504309![]() (US11034717, Compound L1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 990 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504309![]() (US11034717, Compound L1) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504309![]() (US11034717, Compound L1) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 4.00E+3 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 7.5 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 250 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB UniProtKB/SwissProt GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 130 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB UniProtKB/TrEMBL GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 900 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 15 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 120 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 140 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504304![]() (3α,7α,11β-rihydroxy-6α-ethyl-5...) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 730 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 42 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 270 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 240 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
FMR1 autosomal homolog 1 (Dog) | BDBM504310![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/TrEMBL GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 800 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504311![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 29 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Mouse) | BDBM504311![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 210 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Rat) | BDBM504311![]() (3α,7α,11β-trihydroxy-6α-ethyl-...) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 200 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fragile X mental retardation syndrome-related protein 1 (Human) | BDBM504302![]() (3α,7α,11β,23-tetrahydroxy-6α-e...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt DrugBank GoogleScholar | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 7.5 | n/a | n/a | n/a | n/a |
Intercept Pharmaceuticals, Inc. US Patent | Assay Description AlphaScreen was used with the aim of identifying novel modulators by taking advantage of the bimolecular interaction prevailing between FXR and the L... | US Patent US11034717 (2021) | |||||||||||
More data for this Ligand-Target Pair |